Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.21 - $5.13 $1.45 Million - $6.16 Million
1,200,002 New
1,200,002 $1.46 Million
Q2 2022

Aug 15, 2022

SELL
$1.53 - $2.89 $4.48 Million - $8.47 Million
-2,929,993 Reduced 50.69%
2,849,707 $5.22 Million
Q1 2022

May 16, 2022

SELL
$2.67 - $4.68 $667,500 - $1.17 Million
-250,000 Reduced 4.15%
5,779,700 $15.4 Million
Q4 2021

Feb 14, 2022

BUY
$3.87 - $7.39 $17.9 Million - $34.2 Million
4,628,761 Added 330.4%
6,029,700 $26.1 Million
Q2 2021

Aug 13, 2021

SELL
$6.33 - $9.91 $840,744 - $1.32 Million
-132,819 Reduced 8.66%
1,400,939 $8.87 Million
Q1 2021

May 14, 2021

BUY
$6.6 - $9.0 $42,279 - $57,654
6,406 Added 0.42%
1,533,758 $11.9 Million
Q4 2020

Feb 16, 2021

BUY
$6.47 - $7.9 $8,728 - $10,657
1,349 Added 0.09%
1,527,352 $10 Million
Q3 2020

Nov 16, 2020

BUY
$6.55 - $8.83 $75,501 - $101,783
11,527 Added 0.76%
1,526,003 $10.1 Million
Q2 2020

Aug 14, 2020

BUY
$7.4 - $14.64 $3.31 Million - $6.55 Million
447,685 Added 41.97%
1,514,476 $12.6 Million
Q1 2020

May 15, 2020

BUY
$3.61 - $8.6 $98,184 - $233,902
27,198 Added 2.62%
1,066,791 $8.18 Million
Q4 2019

Feb 14, 2020

BUY
$5.17 - $8.91 $254,002 - $437,748
49,130 Added 4.96%
1,039,593 $8.64 Million
Q3 2019

Nov 14, 2019

BUY
$7.38 - $12.25 $15,822 - $26,264
2,144 Added 0.22%
990,463 $7.31 Million
Q2 2019

Aug 14, 2019

BUY
$9.35 - $11.41 $215,676 - $263,194
23,067 Added 2.39%
988,319 $11.1 Million
Q1 2019

May 15, 2019

BUY
$9.5 - $19.16 $538,327 - $1.09 Million
56,666 Added 6.24%
965,252 $10.4 Million
Q4 2018

Feb 14, 2019

BUY
$12.69 - $18.61 $11.5 Million - $16.9 Million
908,586 New
908,586 $13.7 Million

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $69.9M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Rtw Investments, LP Portfolio

Follow Rtw Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rtw Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Rtw Investments, LP with notifications on news.